A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Assess the Efficacy and Tolerability of MK-8141 in Hypertensive Patients
Latest Information Update: 09 May 2022
At a glance
- Drugs MK 8141 (Primary) ; Enalapril
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 18 Jul 2008 Status changed from recruiting to completed, from clinicaltrials.gov record.
- 07 Jan 2008 Updated location and trial centres.
- 05 Dec 2007 Dosing has been started.